tradingkey.logo

Janux Therapeutics Inc <JANX.OQ> expected to post a loss of 39 cents a share - Earnings Preview

ReutersMay 5, 2025 9:06 PM
  • Janux Therapeutics Inc JANX.OQ JANX.O is expected to show a fall in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The San Diego California-based company is expected to report a 55.1% decrease in revenue to $562.5 thousand from $1.25 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Janux Therapeutics Inc is for a loss of 39 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Janux Therapeutics Inc is $76.00​, above​ its last closing price of $32.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.47

-0.46

-0.36

Beat

21

Sep. 30 2024

-0.30

-0.33

-0.51

Missed

-55.7

Jun. 30 2024

-0.29

-0.31

-0.11

Beat

65​

Mar. 31 2024

-0.32

-0.33

-0.30

Beat

9.4

​​Dec. 31 2023

-0.38

-0.39

-0.25

Beat

36.3

Sep. 30 2023

-0.45

-0.47

-0.25

Beat

46.8​

Jun. 30 2023

-0.50

-0.52

-0.42

Beat

18.8

Mar. 31 2023

-0.49

-0.49

-0.42

Beat

14.6

This summary was machine generated May 5 at 21:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI